COVID-19 (Coronavirus) Update: Testing and Information | Vaccine Updates | Visitor Guidelines

A Phase 2 Open-Label, Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Adult Women with Recurrent or Persistent Uterine Serous Carcinoma

Protocol No
ERGOMED-ZN-C3-004
Principal Investigator
William Bradley
Phase
II
Summary
In this study we want to find out more about an investigational drug, ZN-c3, in people with recurrent or persistent Uterine Serous Carcinoma (USC). We want to find out whether the investigational drug ZN-c3 may be an effective treatment for USC, and whether it causes any problems (side effects).
Description
In this study we want to find out more about an investigational drug, ZN-c3, in people with
recurrent or persistent Uterine Serous Carcinoma (USC)
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Sub Category